Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 227 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in... April 23, 2026 Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... May 18, 2021 Tesco is making it even easier to support life-saving research February 3, 2023 EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 Load more HOT NEWS If You Let It, Nursing Will Change Your Life An Updated Overview of Estimates for Cancer Incidence and Mortality in... Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... Can Immunotherapy Succeed in Glioblastoma?
